International Journal of Clinical Research

Objective This study aims to evaluate the effect of pranostat mesylate on the anticoagulant efficacy in hemodialysis patients at different doses. Methods From January 2023 to December 2024,80 maintenance hemodialysis patients in our hospital were randomly divided into two groups: observation group (40 patients, naphthalostat dose 20ml / h) and control group (40 patients, naphthalostat methyllate dose 10ml / h). All patients were treated with routine hemodialysis and underwent anticoagulation with nlimostat mesylate during dialysis. The coagulation effect, changes in coagulation index and incidence of adverse reactions were observed and recorded in both groups. Results More effective in the observation group than in the control group (P＜0.05). After dialysis, the observation group performed better in coagulation parameters such as activated partial thrombin time (APTT) and thrombin time (TT) (P＜0.05). And the complication rate was lower in the observation group (P＜0.05). Conclusion In hemodialysis treatment, the dose of 20ml / h showed better anticoagulant efficacy and higher safety compared with 10ml / h, which is worthy of clinical application.

Naphlimostat mesylate; Hemodialysis; Anticoagulant effect; Coagulation index; Complication rate